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Abstract
Antigen-antibody complexes are central players in an effective immune response. However,
finding those interactions relevant to a particular disease state can be arduous. Nonethe-
less many paths to discovery have been explored since deciphering these interactions can
greatly facilitate the development of new diagnostics, therapeutics, and vaccines. In silico B
cell epitope mapping approaches have been widely pursued, though success has not been
consistent. Antibody mixtures in immune sera have been used as handles for biologically
relevant antigens, but these and other experimental approaches have proven resource
intensive and time consuming. In addition, these methods are often tailored to individual dis-
eases or a specific proteome, rather than providing a universal platform. Most of these
methods are not able to identify the specific antibody’s epitopes from unknown antigens,
such as un-annotated neo antigens in cancer. Alternatively, a peptide library comprised of
sequences unrestricted by naturally-found protein space provides for a universal search for
mimotopes of an antibody’s epitope. Here we present the utility of such a non-natural ran-
dom sequence library of 10,000 peptides physically addressed on a microarray for mimo-
tope discovery without sequence information of the specific antigen. The peptide arrays
were probed with serum from an antigen-immunized rabbit, or alternatively probed with
serum pre-absorbed with the same immunizing antigen. With this positive and negative
screening scheme, we identified the library-peptides as the mimotopes of the antigen. The
unique library peptides were successfully used to isolate antigen-specific antibodies from
complete immune serum. Sequence analysis of these peptides revealed the epitopes in the
immunized antigen. We present this method as an inexpensive, efficient method for identify-
ing mimotopes of any antibody’s targets. These mimotopes should be useful in defining
both components of the antigen-antibody complex.
Introduction
Characterizing the interactions between disease-specific antibodies and their cognate antigens
has proven highly informative in the study of host-pathogen relationships and critical in the
development of effective biomedical products. The discovery of modified antigens or
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autoantigens that are specifically recognized by patient antibodies is of growing importance in
disease research and target development for diagnostics, vaccines, and therapeutics. These
complexes are typically found by querying immune sera against possible ligands in lysates, or
in libraries of proteins or peptides made recombinantly or synthetically. Myriad of binding
assays such as immunoblots [1], ELISAs [2], phage display [3], ribosome display [4], beads [5],
and microarrays [6, 7] have been employed to identify the antigen or epitope recognized by an
antibody. Here we explore using a simple, universal system for epitope identification.
In its original description, phage display was used to survey a library of peptides for binding
to a given antibody[8]. It has now been used extensively to display libraries of peptides or anti-
body fragments, expressed as coat protein fusions on the phages surface, for “panning” against
a particular molecule of interest. Phages are washed across an isolated, immobilized target;
bound recombinant phage are collected and amplified in bacteria for additional rounds of pan-
ning [9]. One of the major drawbacks of phage display is the technique’s reliance on multiple
in vivo steps that cannot be well-controlled and incur biases to the output. For example, any
peptide-coat protein fusions that reduce the fitness of the phage or reduce secretion to the
phage surface will not be well represented if at all. In the initial panning round each phage
recombinant is present in such limited numbers that the probability of a ligand finding a target
can be stochastic. Yet only those recombinants that survive this first round are subsequently
propagated reiteratively. Phage approaches do not lend themselves to high throughput of sam-
ples. As an alternative, in vitro translation systems such as ribosome display have been devel-
oped for studying protein-protein interactions, including antigen/antibody binding. Like
phage, very large libraries can be constructed at minimal cost but the diversities of these recom-
binant mixtures are difficult to maintain and are not reproducible. In addition, apparent diver-
sities can be misleading since the redundancy of the genetic code, incidental stop codons, and
peptide-dependent effects on translation efficiency will limit the ultimately displayed diversity.
In vitro combinatorial synthesis of peptides on beads and microarrays of either proteins or
peptides have been explored as library formats for surveying target binding [5, 10]. Both of
these methods are performed entirely in vitro, and thereby resolve the vagaries of in vivo prop-
agation and biological compatibility. Since peptides are used directly, the issues of translating
DNA are avoided. For the libraries in bead format, the binding steps must be followed by
decoding what is bound through peptide-sequencing, chemical-tracking, or other reading
methods. The synthesis, binding, and decoding steps tend to be laborious, time consuming,
and often lack reproducibility [11]. Array based libraries are more efficient and reliable.
However most of the applications of the above methods focused on known biological tar-
gets. This limited their applications. Each high throughput library can only cover limited prote-
ome. On the other side, the antigens or epitopes within the antigen may not be in the known
proteome. Studies can be confounded by the fact that immune sera often carry antibodies to
mutant, unknown, or even exogenously-derived antigens of a host or pathogen proteome.
Random peptide libraries, whether in vivo or in vitro, provide a means for identifying
mimotopes of unknown antigens and are far more economical since one library can be used for
all screens. For example, an antibody panned against phages displaying random sequence pep-
tide fusions might select recombinants that mimic or hold similarity to a previously unknown
ligand [12]. Microarrays consisting of random sequence peptides or peptoids have been
explored for identifying ligands [13]. Probing of a SPOT synthesis array carrying 5520 random
15-mers with three different monoclonal antibodies followed by substitutional analysis was
able to identify mimotopes of the known wild type epitopes [14]. However, the application of
the random peptide array was limited by the libraries size and the cost and was only applied to
monoclonal antibodies.
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Abbreviations: BSA, Bovine serum albumin; HRP,
Horse radish peroxidase; KLH, Keyhole limpet
hemocyanin; PBS, Phosphate buffered saline; PBST,
Phosphate buffered saline Tween-20; SMC1A,
Structural maintenance chromosome 1A; SMC1Afs,
Structural maintenance chromosome 1A frame-shift;
SMCfs, A 17 amino acid SMC1A frameshift mutant;
TBST, Tris Buffered Saline Tween-20; TMB, 3,3’,5,5’-
Tetramethylbenzidine; TRIS, tris (hydroxymethyl)
aminomethane.
Recently, the immunosignatures technology has been developed as a universal platform to
profile complex antibody mixtures [15]. This technology is based on using arrays of peptides of
10 to 17 amino acids in length chosen form non-natural sequence space. To maximally repre-
sent sequence diversity, which excludes the peptides sequences that are exactly matched to a
natural peptide in the NCBI reference protein database. The random peptide library can be
expanded up to 330,000 unique sequences [16]. The peptide can be printed from pre-synthe-
sized stocks or in situ synthesized. Such a library of random sequence peptides can be used to
identify the disease specific antibody profile from patient sera, including the infection diseases
and different cancers [17–19] and predict vaccine efficacy with the specific antibody profile as
well[20]. Based on the sequence analysis of the array peptides that were specifically recognized
by the antibody or serum from infectious diseases, we can identify the epitopes to the antibod-
ies and track the sequences back to the known antigens that relate to the disease [20–22]. How-
ever, there were two limitations. One is that an antibody could be to an unannotated sequence.
The other is that the actual antibody to the epitope was not created as a reagent.
Here we employ the IMS as a universal platform to design a method for identifying mimics
of disease-relevant epitopes and then show that these mimotopes can capture the disease-rele-
vant antibodies for the further investigation, such as identification of the unknown biological
antigens.
Unique from other platforms that focused on analyzing the purified targets [6, 7] the meth-
ods we demonstrate directly use the serum for the efficient screen for mimics of disease-rele-
vant epitopes. The target epitope may not be highly immunogenic and the antibodies
recognizing the target epitope in the serum may be mixed with irrelevant antibodies with high
affinity to other antigens. Based on these complex conditions, we designed an experiment to
identify mimotopes of a tumor-associated mutant, SMCfs, from a complex immune serum that
contains high affinity polyclonal antibody to the KLH protein. SMCfs is a 17 amino acid novel,
tumor specific frame-shift peptide derived from the mis-splicing RNA of the structural mainte-
nance chromosome 1A protein (SMC1A). The transcript of the SMCfs peptide was first found
in a human EST database. The non-natural sequence peptide microarray, CIM10K, contains
10,000 non-natural sequence peptides chosen from random sequence space. We have shown
that the random sequence peptide microarray can identify the epitopes that are recognized by
monoclonal antibodies [21, 22]. We demonstrate here that this non-natural sequence peptide
microarray can also be used to identify specific mimotopes for antibody enrichment from a
complex immune serum sample. Sequence analysis can identify relevant epitopes of the anti-
body responses.
Material and Methods
Peptides and beads
A number of free peptides were synthesized by Sigma, Inc. Beads for antibody affinity purifica-
tion were prepared in the lab. Peptides were directly synthesized on the TentaGel Beads. The
sequences of these peptides and their assigned names are presented in Table 1.
Rabbit anti-SMCfs sera
Anti-human SMC1Afs serum was generated by Global Peptide Service LLC (Fort Collins, CO).
The 17 amino acid (a.a.) SMC1A frame shift mutant sequence (SMCfs), identified in human
tumor cDNA (CCGIYCHEEPQREDSSI), was synthesized by the peptide synthesis lab at Ari-
zona State University and then conjugated to keyhole limpet hemocyanin (KLH) by Global
Peptide Service LLC.A New Zealand white rabbit was immunized with the SMCfs-KLH conju-
gate. Blood for the experiment was collected at exsanguinations after two immunizations.
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ELISA
ELISA plates were coated with 50 μL of 10 μg/mL of peptide or protein in carbonate coating
buffer and incubated at 4°C overnight. The coated plates were washed 3X with PBST and
blocked with 200 μL of 3% BSA in PBST at 37°C for 30 minutes. The blocked plate was washed
3X with PBST and 50 μL of primary anti-serum or purified antibody diluted in 3% BSA in
PBST was applied. The plate was then incubated at 37°C for 1 hr. After the incubation, the
plate was washed 3X with PBST. The antibody was detected with 50 μL HRP-goat anti-rabbit
IgG diluted 1:2000 in 3% BSA in PBST. After the plate was incubated at 37°C for 1 hr, the plate
was washed 3X and developed with 50 μL TMB for 10 minutes at room temperature. The
development was stopped by adding 50 μL of 0.5 N HCl, and the plate was read with a Spectra-
Max 190 Molecular Devices instrument at OD 450 nm.
Antibody absorption
Specific antibodies were absorbed from the rabbit anti-SMCfs sera by applying the sera to the
SMCfs coated plate. The rabbit sera was diluted 1:250 with 3% BSA in PBST and incubated
with the SMCfs peptide coated plate at 37°C for 1 hr. The unbound antibody in the supernatant
was then removed and applied to another peptide coated well to remove more antibody specific
for the peptide. This process was repeated up to 20 times, and this serum was then later applied
to the peptide microarray at a dilution of 1:500. This same method was used to produce nega-
tive control antibody absorbed sera using the negative control CP1 peptide.
Non-natural sequence peptide array (CIM10K array) printing
The 10,000 non-natural randomly generated peptide sequences were custom synthesized by
Sigma, Inc. These 20-mers were designed with 17 non-natural sequence a.a. residues (excluding
cysteine) and a 3 amino acid (GSC) linker sequence on the C terminus. The C terminal cysteine
binds to a sulfo-SMCC coated aminosilane glass slide. The solutions of different non-natural
sequence peptides were printed onto the glass slide using a Nanoprint 60 instrument (Array It
Technologies).
Table 1. Amino acid sequences of free peptides and peptide-bead conjugates.
Assigned Name Sequence Description
SMCfs CCGIYCHEEPQREDSSI human SMC1A frameshift 17mer peptide
SMCfs-27 TAIIGPNGSGCCGIYCHEEPQREDSSI human SMC1A frameshift 27mer peptide
RP1 TISKYVMVEPMRQHEEWGSC random peptide SMCfs mimotope
RP2 AVSHQEMNEGEQGPMREGSC random peptide SMCfs mimotope
RP3 RVGEMPMREYDISGGSGGSC random peptide SMCfs mimotope
RP4 TAFYRTLTKHEVDPGIAGSC random peptide SMCfs mimotope
CP1 AVLLMCQLYQPWMCKEYYRLL negative control peptide which is not a mimotope of SMCfs
SMCfs-B CCGIYCHEEPQREDSSI human SMC1A frameshift 17mer peptide conjugated to Tentagel beads
RP1-B TISKYVMVEPMRQHEEWGSC random peptide SMCfs mimotope conjugated to Tentagel beads
RP2-B AVSHQEMNEGEQGPMREGSC random peptide SMCfs mimotope conjugated to Tentagel beads
RP3-B RVGEMPMREYDISGGSGGSC random peptide SMCfs mimotope conjugated to Tentagel beads
RP4-B TAFYRTLTKHEVDPGIAGSC random peptide SMCfs mimotope conjugated to Tentagel beads
CP2-B ATKAAIPGPNTVPRAP negative control peptide which is not a mimotope of SMCfs conjugated to Tentagel beads
doi:10.1371/journal.pone.0157462.t001
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Application of sera to non-natural sequence peptide array
Rabbit sera samples were applied to the non-natural sequence peptide microarray using a
Tecan HS 4800 Pro microarray hybridization station. Slides were first washed for 30s with
TBST, and then blocked with a blocking buffer consisting of BSA, mercaptohexanol, Tween 20,
and PBS for 1 hr at 23°C. Duplicate samples of sera were diluted 1:500 in an incubation buffer
consisting of BSA, Tween 20, and PBS and incubated with the slide for 1 hr at 37°C. The slide
was then washed, and 5 nM of goat anti-rabbit IgG conjugated with Alexa Fluor 647 dye was
applied for 1 hour at 37°C. The slide was then washed and dried for 5 min.
Scanning and analysis of array
The slides were scanned with an Agilent Technologies DNAMicroarray Scanner with Surescan
High-Resolution Technology instrument and analyzed with GenePix Pro 6.0 software to deter-
mine the fluorescence intensity of each spot. GeneSpring GX 7.3, Microsoft Excel, simple cus-
tom Java code, and GraphPad Prism 4 were then used to perform further analysis of this data.
Antibody affinity purification
Total IgG of the rabbit anti-SMCfs sera was purified using Pierce Protein A/G Agarose beads
according to the protocol of the manufacturer. 1 ml of the TentaGel beads with specific pep-
tides were embedded in a column. 3 ml of the purified total IgG was added to the column and
incubated with the beads for 1 hr at room temperature. The column was then washed with 10
ml PBST. The specific IgG was eluted with 4 fractions of 1 ml IgG Elution Buffer (Pierce, Inc)
and each fraction was neutralized with 100 ul 1M TRIS (pH8.0). All of the eluted fractions
were measured at an absorbance of 280nm. The two fractions with the highest absorbance
were combined and used for further analysis at a 1 to 40 dilution in 3% BSA in PBST.
Analysis of motifs
GLAM2 software [23] was used to identify and score common motifs among the high binding
peptides. Bepipred was used to find and score B cell epitopes [24].
Results and Discussion
Screening of anti-SMCfs serum on non-natural sequence peptide array
To identify non-natural sequences recognized by the immune serum, both naïve and SMCfs-
immune rabbit sera were applied to the array. We identified a total of 108 non-natural
sequence peptides which exhibited high specificity to the immune serum relative to the naïve
rabbit control serum based on the t-test (p<0.0001)(Fig 1, S1 Table). The anti-SMCfs immune
serum contains polyclonal antibodies to both SMCfs peptide and KLH, the carrier protein.
Therefore, these 108 peptides carry potential mimotopes of either the SMCfs peptide or KLH
protein.
Sequence analysis to identify the mimic epitope to KLH protein
Since the KLH is a large and highly immunogenic antigen, the rabbit anti-serum contained
high titer antibodies to the KLH protein. Mimotopes to KLH among the 108 SMCfs peptides
were investigated (S2 Table). When the 108 peptides selected for higher binding to SMCfs sera
than to naive sera are compared to the KLH1 and KLH2 sequences (a total of 6,830 aa) with
GLAM2 individually, then 54 of the 108 peptides have a GLAM2 score above 11.7. The total
collection of scores ranges from 7.93 to 17.8 with 11.7 at the 50th percentile. Among the top 54
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peptides by GLAM2 score, 2 contain mimotopes that align with HAEDHFYI, 2 with HHEKH-
HEDHH, 2 with DSFDYQNRFRY, 2 with DKEYYDVWRWRNKVMPNPFA, 2 with
HHANTDRIW, 2 with WGFYRAYHF, and the rest of the mimotopes align with various
regions of the KLH protein sequence. These results demonstrate again that the IMS could effi-
ciently identify the epitopes to the known antigens directly from the complex serum.
SMCfs immune serum absorption and array analysis
Compared to KLH, the SMCfs peptide is much smaller and lower immunogenic. To distin-
guish the mimotopes of the SMCfs peptide from that of KLH, we specifically depleted the anti-
SMCfs antibodies from the immune serum through iterative antibody absorption steps. ELISA
analysis confirmed that anti-SMCfs antibodies were partially depleted from the original serum
after 11 rounds of absorption and further depleted after 20 rounds (Fig 2A).
The anti-SMCfs antibody-depleted samples, as well as the negative control serum, were
applied to the CIM10K array. Reactivity profiles of these samples against the 108 peptides
selected in the original screen were compared (Fig 2B, S3 Table). Different binding profiles
Fig 1. Selective binding of anti-SMCfs serum to a library of non-natural sequence peptides printed on
amicroarray. Polyclonal rabbit serum generated against the SMCfs peptide conjugated to KLH and naive
rabbit serum were applied to an array of 10,000 synthetic peptides of randomly generated sequence.
Student’s t-test analyses comparing the probing results identified 108 non-natural sequence 20-mers with
differential binding to the immune versus naïve sera (p-values <0.0001). These differences in peptide-binding
intensities are visually represented as a heatmap.
doi:10.1371/journal.pone.0157462.g001
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were observed among the differentially depleted anti-SMCfs serum samples. Peptide mimo-
topes of SMCfs would be predicted to react similarly in the presence of the non-absorbed and
control-peptide absorbed (anti CP1-antibody depleted) immune serum samples. On the other
hand, peptides carrying a SMCfs mimotope would be predicted to display decreased reactivity
in the presence of the anti-SMCfs antibody depleted serum sample. Based on these criteria of
specificity, we developed a formula to score each of the 108 peptides (Eq 1). Four top scoring
peptides, designated RP1, RP2, RP3, and RP4, were re-synthesized for testing as functional
mimotopes.
Eq 1. Score assignment for random peptide SMCfs specificity. A high score indicates
that the given random peptide binds to antibodies with high specificity for the SMCfs sequence,
and a low score indicates the opposite. Smax is the maximum signal intensity of the peptide
with unabsorbed SMCfs sera. S20X is the intensity of the peptide with sera after SMCfs binding
antibodies have been absorbed twenty times. SCP is the intensity of the peptide with sera after
CP1 binding antibodies have been absorbed twenty times. The CP1 peptide is a negative con-
trol peptide with no sequence similarity to SMCfs.
Smax  S20X
Smax
þ SCP
Smax
ð1Þ
Fig 2. Analyses of anti-SMCfs serum pre-absorbed against SMCfs peptide. A. Validation of SMCfs
antibody depletion from immune serum. The serum-absorption steps (11or 20) refer to the number of
iterative rounds of SMCfs-peptide or CP1-peptide absorption experiments conducted before application of the
depleted serum to ELISA plates coated with SMCfs peptide. Error bar indicates SD of the duplication.B. Signal
intensity changes in anti-SMCfs serum binding following peptide-specific depletion. The depleted
immune sera samples were applied to the peptide array. Binding intensities to the 108 non-natural sequence
peptides, which were shown to be selectively recognized by the original anti-SMCfs serum, are displayed as a
heatmap for their visual comparison. There is an 850 fold difference between the lowest fluorescence intensity
and the highest intensity. Four anti-SMCfs sera samples were applied to the peptide array, 1) non-absorbed
anti-SMCfs serum, 2) anti-SMCfs serum absorbed 11x against SMCfs peptide, 3) anti-SMCfs serum absorbed
20x against SMCfs peptide, 4) anti-SMCfs serum absorbed 20x against the CP1 negative control peptide.
doi:10.1371/journal.pone.0157462.g002
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ELISA validation of the binding specificity of RP1-RP4 to anti SMCfs
immune serum
To assess the specificity of anti-serum binding to the four putative mimotopes, we first ana-
lyzed the reactivity of the selected peptides to the immune serum by ELISA (Fig 3A). Com-
pared to the negative control peptide CP1, all four mimotopes had significant though varied
reactivity levels to the immune serum. However, the reactivity levels of the four mimotopes
were lower than that of the original SMCfs peptide, which had a saturated signal at 1:5000
dilution.
To test the possibility that RP1-RP4 are mimotopes of a KLH protein epitope rather than
SMCfs, we measured the reactivity of the four selected random peptides, the original SMCfs
peptide, and CP1 to the polyclonal KLH immune serum (Fig 3B). All six of these peptides
showed similarly low reactivity levels when probed with the KLH immune serum, whereas the
KLH protein-antigen displayed saturated signal against the anti-KLH serum. These ELISA
analyses indicate that the four random peptides act as mimotopes of the SMCfs peptide; and
indicate that each mimotope contains a partial or suboptimal epitope of the cognate SMCfs
peptide.
Affinity purification of anti-SMCfs antibodies with the array-selected
peptides
To determine whether RP1 to RP4 can be used to selectively purify antibodies specific to the
original immunogen, we prepared affinity purification columns with each of four random pep-
tides (RP1 to RP4), SMCfs, and an irrelevant peptide as negative control (CP2-B). The binding
specificities of the affinity-purified antibodies were measured by determining the activity of the
eluted antibodies against SMCfs-27 or KLH antigen (Fig 4). The SMCfs-27 is comprised of the
sequence of SMCfs plus the 10 amino acids found in the wild type protein immediately
upstream of the frame-shift. The SMCfs-27and SMCfs peptide had similar reactivity to the
SMCfs immune serum (data not shown). The antibodies purified by RP1-RP4 specifically rec-
ognized the original immunogen, not the KLH protein. This result confirms the specificity of
the mimotopes screened by the CIM10K array, and validates this approach of using a mimo-
tope to purify specific antibodies from a complex antibody mixture.
Fig 3. ELISA determinations of anti-SMCfs sera binding to array-selected peptides. A. Immune serum.
Rabbit polyclonal anti-SMCfs serum was applied to the SMCfs peptide, four of the array-selected peptides, and a
control peptide. The SMCfs peptide is the positive control.B. Control serum.Mouse polyclonal anti-KLH serum
was applied to the same set of peptides described in A. The KLH is the positive control. Error bar indicates SD of
the duplication.
doi:10.1371/journal.pone.0157462.g003
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Measuring cross-reactivity of anti-SMCfs antibodies to antigen
mimotopes
The antibody samples that were affinity-purified from the SMCfs immune serum with the
SMCfs peptide or with the array-selected mimotopes display more than one cross-reactivity
group as measured by ELISA (Fig 5). Antibodies purified with the RP1, RP2, or RP3 peptides
cross-reacted strongly with one another; however, antibodies purified with the RP4 only recog-
nized the RP4 peptides. One explanation for this behavior is that RP1, RP2, andRP3 possess a
Fig 4. ELISA analysis of affinity-purified antibodies. The SMCfs peptide, four highly array-reactive
peptides, and a control peptide (CP2-B) were synthesized on Tenta-gel beads. These were used to prepare
individual affinity columns. Purified total IgG of the anti-SMCfs serum was applied; bound antibodies were
eluted. These peptide-purified antibody samples were analyzed by ELISA against SMCfs-27 coated or KLH
coated plates. Error bar indicates SD of the duplication.
doi:10.1371/journal.pone.0157462.g004
Fig 5. Differential binding of affinity-purified anti-SMCfs antibodies to SMCfs versus library-derived
andmimotopes. The antibodies affinity purified by SMCfs-B or four library-selected peptide bound to beads
(RP1-B through RP4-B) were measured for reactivity against the SMCfs and mimotope peptides by ELISA
and displayed in a three-dimensional bar graph.
doi:10.1371/journal.pone.0157462.g005
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similar sequence or structural motif whereas RP4 carries a unique one. Sequence analysis
described in section 3.6 below supports this hypothesis. Notably, all four mimotope-purified
antibody samples display the highest reactivity levels against the cognate SMCfs immunogen,
rather than the sequence ligand used to purify them. This suggests three points. First, the non-
natural sequences appear to have been selected from the arrayed-library based on their SMCfs-
like binding characteristics, as opposed to binding to some perhaps related but different target.
Second, the sampling of non-natural sequence space afforded by this library may be too sparse
to provide mimotopes that are close enough to the true SMCfs epitopes to achieve higher bind-
ing activity. Notably, the CIM10K array displays 104 different peptide sequences; whereas 1021
unique 17-mers are possible. Third, even for a peptide as short as 17aa, the mimotopes can
resolve two different binding sites.
Sequence Analyses to identify the potential epitope in the unknown
antigen
From the mimotpe identification to the validation, we did not use the sequence information of
the original SMCfs peptide. To test the possibility of using the sequence analysis of the mimo-
topes to identify epitope of the unknown antigen, we did the sequence analysis of both the
SMCfs and RP1 to RP4 peptides. The epitope search software Bepipred was used to predict
strong B cell epitopes within the unique SMC1A frameshifted sequence. The highest amino
acid score was assigned to the proline within HEEPQRE. The GLAM2 software was used to
identify sequences in RP1 through RP4 with similarity to sequence stretches found in SMCfs.
The RP1 peptide contains two motifs: HEE and YXXXXPMRQ, although they are in reverse
order relative to those sequences of SMCfs. Note that previous experiments have also identified
high binding peptides with inverted sequences relative to the original epitope, but these inver-
sions typically involved just two amino acids [25]. RP2 contains PMREGS and RP3 contains
EMPMRE. RP4 contains only the simple dimer HE (Table 2). This analysis shows that three of
the four peptides contain a PQRE-like motif found in the cognate SMCfs peptide. Although
RP1 contains reversed YXXXXPMRQ and HEE motifs, the peptide is specifically recognized
by anti-SMCfs antibodies. This may indicate that i) the HEE motif acts independently of the
PQRE-motif, ii) they work in concert but order is not important, iii) or that HEE is not relevant
to binding. There is no conserved linear motif of the SMCfs in the RP4 suggesting that RP4
may contain the mimotope with the similar topological structure. This will be another advan-
tage of the random peptide library for the mimotope screen.
Note that the RP1-4 peptides which have been the focus of this paper were not the only pep-
tides among the 108 selected peptides which exhibited good mimotope matches of the SMCfs
Table 2. Motifs in common between RP1-4 and SMCfs as identified by the GLAM2 software.
Sequence ID Sequence Motif in Peptide Matching with SMCfs Matching SMCfs sequence
SMCfs CCGIYCHEEPQREDSSI - -
RP1 TISKYVMVEPMRQHEEWGSC YXXXXPMRQ YXXXXPQRE
PMRQ PQRE
HEE HEE
RP2 AVSHQEMNEGEQGPMREGSC PMREGS PQREDS
PMRE PQRE
RP3 RVGEMPMREYDISGGSGGSC EMPMRE EEPQRE
PMRE PQRE
RP4 TAFYRTLTKHEVDPGIAGSC HE HE
doi:10.1371/journal.pone.0157462.t002
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peptide (S4 Table). When the 108 peptides selected for higher binding to SMCfs sera than to
naive sera are compared to the SMCfs peptide with GLAM2 individually, then 56 of the 108
peptides have a GLAM2 score above 4.50. The total collection of scores ranges from 2.31 to
8.70 with 4.55 at the 50th percentile. The 5 high intensity peptides have GLAM2 scores that
place them in the top 22 peptides of the 108 peptide list sorted by GLAM2 score. The top 4 pep-
tides ranked by SMCfs score are in the top 16 peptides of the 108 peptide list sorted by GLAM2
score. Therefore, there seems to be a good correspondence between intensity detected from the
array and the GLAM2 score for each peptide. Among the top 56 peptides by GLAM2 score, 28
contain mimotopes that align with GIYCH, 30 contain mimotopes that align with
CHEEPQRE, and 6 contain mimotopes that align with DSSI of the CCGIYCHEEPQREDSSI
SMCfs peptide.
There was a good correspondence between GLAM2 scores for RP1-4 aligned with the
SMCfs peptide and scores from the peptide microarray. The GLAM2-assigned similarity scores
of the mimotopes to SMCfs led to a ranking of the top 4 peptides in the same order that they
were ranked by the array absorption scoring described in section 3.2. For example, the RP1
peptide holds two motifs in common with the original antigen, exhibits the highest intensity
on the peptide microarray, and scored the highest by the GLAM2 software. By contrast, the
absorbance intensities obtained in the ELISA experiment did not yield rankings identical with
the other readouts. This suggests that the array format may enable higher resolution detection
of antibody-peptide interactions. Taking together, the sequence analysis of the specific array
peptides showed the advantage of our high density random peptide array for identifying the
epitopes of unknown antigen.
Conclusion
The techniques demonstrated here could be inexpensively and generally applied for both mimo-
tope and true-epitope discovery. We have demonstrated that non-natural sequence peptide
arrays can be used to identify mimotopes of specific antibodies without knowing the sequence
information of the primary epitope. This high density pepetide array platform is sensitive enough
to identify at least two different specific antibodies to a simple peptide from the highly reactive
antibodies which recognize KLH, a highly immunogenic antigen. The sequence analysis of the
identified mimotopes can help identify the true B cell epitopes of an immunogen. Furthermore,
the selected mimotopes can be used to purify this specific polyclonal antibody from the complex
milieu of a serum sample for further analysis. In addition to be being a universal platform for the
epitope exploration of any antibody, the non-natural sequence peptide array requires no assump-
tions or information relative to the true epitope of an immunogen, and therefore evenmimotopes
of newly mutated antigens can be discovered. As the SMCfs peptide was not an annotated, but
frame-shift antigen, this method may allow discovery of the immunogenic epitopes of non-anno-
tated antigens, such as novel mutations in tumor cells.
We suggest that mimotopes can be used to identify medically important antibodies and
their natural targets. Additionally, mimotopes can be used as alternatives to a true epitope if
they are found to carry advantageous properties. These may include greater stability, simpler
production, or differential affinity relative to an autoantigen. These are all important attributes
for successful drug or therapeutic development.
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